Tools to customize and optimize your biotherapeutic lead candidate

Assess your candidate’s developability profile with Lonza’s proprietary Epibase® and manufacturability in silico platforms. Re-engineer your protein to design your optimal biotherapeutic lead candidate.

We can screen for undesirable features and identify desirable substitutions that modify and enhance your protein's properties such as its activity, immunogenicity and stability.

Example programs include:

  • Deimmunization
  • Fc fusion protein design
  • Half-life extension
  • Manufacturability improvement
  • Removal of high risk post-translational modifications
  • Reduction of aggregation hotspots
  • Improvement of stability

Once variants have been designed, they can be expressed in a program tailored to your specific needs.

Our locations

Locations where this service is provided


Cambridge, United Kingdom

Early Development Services offer a portfolio of preclinical risk assessment solutions that utilize in silico and in vitro assessment for stability, antibody humanization, protein engineering as well as providing non-GMP protein production services.

Learn more